Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis (Q37349855)

19 August 2017

1 reference

title

Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis (English)

1 reference

19 August 2017

0 references

1 reference

1

Christopher Dye

1 reference

PubMed ID

19079354

19 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

Nature Reviews Microbiology

19 August 2017

1 reference

19 August 2017

7

1 reference

19 August 2017

1

1 reference

19 August 2017

81-87

1 reference

https://scigraph.springernature.com/pub.10.1038/nrmicro2048

19 August 2017

0 references

cites work

Lack of development of new antimicrobial drugs: a potential serious threat to public health.

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Multidrug-resistant tuberculosis management in resource-limited settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Long-term follow-up for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Beijing/W genotype Mycobacterium tuberculosis and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

WHO's new Stop TB Strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

XDR-TB in South Africa: no time for denial or complacency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Antibacterial resistance worldwide: causes, challenges and responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

New tuberculosis therapeutics: a growing pipeline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Medicine. A portfolio model of drug development for tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Will tuberculosis become resistant to all antibiotics?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Worldwide Incidence of Multidrug‐Resistant Tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Global incidence of multidrug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Challenges in estimating the total burden of drug-resistant tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Underreported threat of multidrug-resistant tuberculosis in Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Worldwide emergence of extensively drug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Criteria for the control of drug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

The effect of drug resistance on the fitness of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Predicting antibiotic resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Horizontal Transfer of a Virulence Operon to the Ancestor of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

IS6110, a Mycobacterium tuberculosis complex-specific insertion sequence, is also present in the genome of Mycobacterium smegmatis, suggestive of lateral gene transfer among mycobacterial species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Contribution of horizontally acquired genomic islands to the evolution of the tubercle bacilli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

The clinical management of drug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Comprehensive treatment of extensively drug-resistant tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Long term efficacy of DOTS regimens for tuberculosis: systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Treatment Outcomes in Extensively Resistant Tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

The competitive cost of antibiotic resistance in Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Predicting the future of XDR tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Does DOTS work in populations with drug-resistant tuberculosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Can DOTS control multidrug-resistant tuberculosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Age-period-cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Environmental infection control of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Epidemiology and treatment of multidrug resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

The effect of tuberculosis control in China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2048

Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries

31 March 2020

1 reference

12 December 2020

Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore.

1 reference

12 December 2020

XDR-TB: entering the post-antibiotic era?

1 reference

12 December 2020

The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco.

1 reference

12 December 2020

Management of extensively drug-resistant tuberculosis in Peru: cure is possible

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRMICRO2048

1 reference

19 August 2017

1 reference

PubMed ID

19079354